[Articles] Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial

Attention!

On Life Science Network, we import abstract of articles published in the most popular journals. In addition, members of our network often upload full article pdfs of their research.

To access all content shared in our network and the source link, please sign up for an account. If you already have an account, sign in, or connect with LinkedIn, Google.